Viewing Study NCT02233894


Ignite Creation Date: 2025-12-25 @ 1:39 AM
Ignite Modification Date: 2026-01-06 @ 11:22 AM
Study NCT ID: NCT02233894
Status: COMPLETED
Last Update Posted: 2014-09-09
First Post: 2014-09-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease
Sponsor:
Organization:

Raw JSON

{'hasResults': False, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D029424', 'term': 'Pulmonary Disease, Chronic Obstructive'}], 'ancestors': [{'id': 'D008173', 'term': 'Lung Diseases, Obstructive'}, {'id': 'D008171', 'term': 'Lung Diseases'}, {'id': 'D012140', 'term': 'Respiratory Tract Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'PROSPECTIVE', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 526}, 'patientRegistry': False}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2001-02'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2014-09', 'lastUpdateSubmitDate': '2014-09-08', 'studyFirstSubmitDate': '2014-09-08', 'studyFirstSubmitQcDate': '2014-09-08', 'lastUpdatePostDateStruct': {'date': '2014-09-09', 'type': 'ESTIMATED'}, 'studyFirstPostDateStruct': {'date': '2014-09-09', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2002-05', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Change in overall severity of the clinical picture', 'timeFrame': '3 months'}], 'secondaryOutcomes': [{'measure': 'Assessment of efficacy by investigator on a 4-point scale', 'timeFrame': 'after 3 months'}, {'measure': 'Assessment of efficacy by patient on a 4-point scale', 'timeFrame': 'after 3 months'}, {'measure': 'Number of patients with adverse drug reactions', 'timeFrame': '3 months'}, {'measure': 'Assessment of tolerability by investigator on a 4-point scale', 'timeFrame': 'after 3 months'}, {'measure': 'Assessment of tolerability by patient on a 4-point scale', 'timeFrame': 'after 3 months'}]}, 'conditionsModule': {'conditions': ['Pulmonary Disease, Chronic Obstructive']}, 'descriptionModule': {'briefSummary': 'Study to obtain further information on the tolerability and efficacy of Atrovent® inhalets in the treatment of Chronic Obstructive Pulmonary Disease under conditions of daily practice'}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '40 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Patient with chronic obstructive pulmonary disease recruited at general practitioners', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Patients of both genders older than 40 years, who suffer from Chronic Obstructive Pulmonary Disease\n* Only patients who have not been treated with Atrovent® within the last year are to be considered for inclusion\n\nExclusion Criteria:\n\n* Contraindications listed in the Instructions for Use/Summary of Product Characteristics for Atrovent® metered dose inhaler'}, 'identificationModule': {'nctId': 'NCT02233894', 'briefTitle': 'Post-marketing Surveillance of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease', 'organization': {'class': 'INDUSTRY', 'fullName': 'Boehringer Ingelheim'}, 'officialTitle': 'Post-marketing Surveillance (as Per § 67(6) AMG [German Drug Law]) of Atrovent® Inhalets in Chronic Obstructive Pulmonary Disease', 'orgStudyIdInfo': {'id': '244.2502'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Chronic obstructive pulmonary disease patients', 'interventionNames': ['Drug: Atrovent® - inhalets']}], 'interventions': [{'name': 'Atrovent® - inhalets', 'type': 'DRUG', 'armGroupLabels': ['Chronic obstructive pulmonary disease patients']}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Boehringer Ingelheim', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}